Company Filing History:
Years Active: 2011
Title: Mathew C Pellegrini: Innovator in Molecular Screening Technologies
Introduction
Mathew C Pellegrini is a notable inventor based in Bedminster, NJ (US). He has made significant contributions to the field of molecular biology, particularly in the area of screening compounds that can modulate translation processes in cells. His work is essential for advancing pharmaceutical research and development.
Latest Patents
Mathew C Pellegrini holds a patent for "Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay." This invention relates to a method for screening and identifying compounds that interact with specific ribonucleic acids (RNA). The patent outlines a process for identifying compounds that bind to regions of the 28S ribosomal RNA, utilizing direct, noncompetitive binding assays to screen libraries of compounds. This method provides a sensitive assay for high-throughput screening, which is crucial for identifying potential pharmaceutical leads.
Career Highlights
Pellegrini is currently associated with PTC Therapeutics, Inc., where he applies his expertise in molecular screening technologies. His innovative approaches have the potential to lead to breakthroughs in the treatment of various diseases by targeting specific RNA interactions.
Collaborations
Mathew has collaborated with notable colleagues, including Ellen Welch and Neil Gregory Almstead. These partnerships enhance the research environment and contribute to the advancement of their collective work in molecular biology.
Conclusion
Mathew C Pellegrini's contributions to the field of molecular screening are invaluable. His innovative patent and work at PTC Therapeutics, Inc. highlight his role as a key figure in advancing pharmaceutical research. His efforts continue to pave the way for new therapeutic developments.